Program
VV119
A development code. Also written as “VV119 (in healthy adult subjects)”, “VV119(in adult patients with schizophrenia)” and “VV119(SAD)”.
Its studies are mostly in Schizophrenia, led by Vigonvita Life Sciences.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Vigonvita Life Sciences | 44 open or running | phase 2since Jul 6, 2026 | Oct 17, 2023 | Oct 31, 2027phase 2 · NCT07703956 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 17, 2023First study: phase 1 study in SchizophreniaFirst studyNCT06105151 · 82 enrolled · China
- Jul 2, 2024Phase 1 study in SchizophreniaNCT06504290 · 40 planned · China
- Nov 16, 2025Phase 1 study in Healthy VolunteersNCT07240636 · 16 planned · China
- Jul 6, 2026Phase 2 study in SchizophreniaPhase 2 reachedNCT07703956 · 500 planned · China
Ahead
- Oct 31, 2027Primary completion: phase 2 study in SchizophreniaNCT07703956
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07703956Schizophrenia · China | 2 | Not yet recruiting | Oct 31, 2027 | 500 |
| NCT07240636Healthy Volunteers · China | 1 | Recruiting | Oct 2026 | 16 |
| NCT06504290Schizophrenia · China | 1 | Recruiting | Oct 1, 2026 | 40 |
| NCT06105151Schizophrenia · China | 1 | Active, not recruiting | Oct 2026 | 82 |
How it is read
Names in the registry
- “VV119”, 2 entries
- “VV119 (in healthy adult subjects)”, 1 entry
- “VV119(in adult patients with schizophrenia)”, 1 entry
- “VV119(SAD)”, 1 entry
- “VV119(FE)”, 1 entry
Codes read as this program: VV119.
Conditions, from the studies’ own filings
- Schizophrenia, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.